Consensus recommendation for the treatment of generalised Myasthenia Gravis with anti-acetylcholine receptor antibodies (gMG AChR+) in Spain

Rare Pub Date : 2025-01-01 DOI:10.1016/j.rare.2024.100051
Elena Cortés-Vicente , Raquel Hernández , Eva Martínez , Julio Pardo , Francisco Javier Rodríguez de Rivera , on behalf of the Neuromuscular Diseases Study Group (GEEN) of the Spanish Society of Neurology
{"title":"Consensus recommendation for the treatment of generalised Myasthenia Gravis with anti-acetylcholine receptor antibodies (gMG AChR+) in Spain","authors":"Elena Cortés-Vicente ,&nbsp;Raquel Hernández ,&nbsp;Eva Martínez ,&nbsp;Julio Pardo ,&nbsp;Francisco Javier Rodríguez de Rivera ,&nbsp;on behalf of the Neuromuscular Diseases Study Group (GEEN) of the Spanish Society of Neurology","doi":"10.1016/j.rare.2024.100051","DOIUrl":null,"url":null,"abstract":"<div><div>Myasthenia Gravis (MG) is a rare, chronic, and autoimmune neuromuscular disease caused by presence of pathogenic immunoglobulins G (IgG) targeting postsynaptic components of the neuromuscular junction resulting in muscle weakness and fatigability. Currently therapies for MG are focused on improving clinical symptoms aiming to achieve remission or minimal expression of symptoms. Immunologically, 85 % of patients with generalised MG (gMG) have autoantibodies against the acetylcholine receptor (AChR+). In Spain, several reviews on MG treatment have been published, but the approval of new molecules with more targeted mechanisms of action indicated for gMG AChR+ makes necessary to update the current treatment protocol to reflect the latest evidence and align it with current recommendations from national and international clinical practice.</div></div>","PeriodicalId":101058,"journal":{"name":"Rare","volume":"3 ","pages":"Article 100051"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rare","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950008724000346","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Myasthenia Gravis (MG) is a rare, chronic, and autoimmune neuromuscular disease caused by presence of pathogenic immunoglobulins G (IgG) targeting postsynaptic components of the neuromuscular junction resulting in muscle weakness and fatigability. Currently therapies for MG are focused on improving clinical symptoms aiming to achieve remission or minimal expression of symptoms. Immunologically, 85 % of patients with generalised MG (gMG) have autoantibodies against the acetylcholine receptor (AChR+). In Spain, several reviews on MG treatment have been published, but the approval of new molecules with more targeted mechanisms of action indicated for gMG AChR+ makes necessary to update the current treatment protocol to reflect the latest evidence and align it with current recommendations from national and international clinical practice.
西班牙对抗乙酰胆碱受体抗体(gMG AChR+)治疗广泛性重症肌无力的共识建议
重症肌无力(MG)是一种罕见的慢性自身免疫性神经肌肉疾病,其病因是致病性免疫球蛋白G (IgG)靶向神经肌肉连接处的突触后组分,导致肌肉无力和疲劳。目前治疗MG的重点是改善临床症状,旨在达到缓解或症状的最小表达。免疫方面,85% %的全身性MG (gMG)患者有针对乙酰胆碱受体(AChR+)的自身抗体。在西班牙,已经发表了几篇关于MG治疗的综述,但批准具有更靶向作用机制的新分子用于gMG AChR+ 使得有必要更新当前的治疗方案,以反映最新的证据,并使其与国家和国际临床实践的当前建议保持一致。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信